Moderna vs Novavax Which Is Superior?

Both Moderna and Novavax are biotechnology companies that have gained significant attention in the stock market due to their respective COVID-19 vaccine developments. Moderna's mRNA vaccine has been widely distributed and proven to be highly effective, leading to a surge in their stock value. On the other hand, Novavax has also made strides in vaccine development, with promising clinical trial results, causing their stock to rise. Investors are closely watching the competition between these two companies as they continue to play a crucial role in the fight against the pandemic.

Moderna or Novavax?

When comparing Moderna and Novavax, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Moderna and Novavax.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Moderna has a dividend yield of -%, while Novavax has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Moderna reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Novavax reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Moderna P/E ratio at -7.19 and Novavax's P/E ratio at -4.93. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Moderna P/B ratio is 1.34 while Novavax's P/B ratio is -2.67.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Moderna has seen a 5-year revenue growth of 10.87%, while Novavax's is 4.26%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Moderna's ROE at -17.68% and Novavax's ROE at 44.82%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $41.06 for Moderna and $8.71 for Novavax. Over the past year, Moderna's prices ranged from $35.80 to $170.47, with a yearly change of 376.17%. Novavax's prices fluctuated between $3.53 and $23.86, with a yearly change of 575.92%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.